Analysed ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) News Sources
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
30-04-2026
yahoo.com
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
07-05-2026
yahoo.com
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
04-06-2026
marketbeat.com
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
30-06-2026
yahoo.com
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06-08-2026
yahoo.com
What is the current price of ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ)?
The current price of ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) is $2.
ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) since the previous trading day is $-0.05.
ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) since the previous trading day is -2.439%.
What is the most recent average sentiment score for ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ)?
The most recent average sentiment score for ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ)?
The most recent sentiment for ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ) is .
SEC-8K** Filing Available For ALX ONCOLOGY HOLDINGS INC (ALXO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.